Trial: 202103029

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination with Pembrolizumab or Binimetinib in Adult Patients with Advanced Solid Tumors

Phase

I/II

Principal Investigator

Morgensztern, Daniel

Disease Site

Colon; Lung; Pancreas; Rectum

Learn more about this study at: clinicaltrials.gov